Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Bayer AG said on Thursday it had agreed to sell more crop science businesses to BASF in a deal that fulfills undertakings to the European Union and other regulators as part of its takeover of Monsanto Co.

The package, being sold for up to 1.7 billion euros ($2.1 billion), includes its global vegetable seeds business, certain seed treatments and digital farming activities with total sales of 745 million euros in 2017.

“With this move, we are implementing the corresponding undertakings made to the European Commission and other regulatory authorities to allow the successful closing of the Monsanto transaction,” Werner Baumann, Chairman of the Board of Management of Bayer AG, said in a statement.

Story continues below advertisement

The German drug and crop chemical maker’s bid to buy seed and chemical company Monsanto Co is on track to win U.S. antitrust approval by the end of May, unless there is a last-minute complication, two people familiar with the matter said earlier on Thursday.

The transaction, if it closes as seems likely, will create a company commanding more than a quarter of the combined world market for seeds and pesticides in the fast-consolidating farm supplies industry.

The U.S. Justice Department said in March it was pressing on with its antitrust review of the deal.

The merger has already cleared key hurdles. Russia’s antitrust regulator FAS approved it last week and the European Commission last month gave conditional clearance, following a conditional nod in Brazil.

Also last week, the German group raised 3 billion euros ($3.7 billion) by selling new shares to Singapore’s state investment company, with further moves expected to increase its capital.

Bayer previously said it would only launch a cash call once it had sufficient clarity that the deal, signed in September 2016, would get the go-ahead.

It had already pledged to sell certain seed and herbicide assets for 5.9 billion euros ($7.2 billion) to BASF, as well as its vegetable seeds business.

Report an error
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Comments are closed

We have closed comments on this story for legal reasons or for abuse. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies